Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Additions to Study Design
View:
Post by Eoganacht on Mar 22, 2024 3:54pm

Additions to Study Design

• Surgeon has the option to deliver up to 2 more re-induction Study Procedures, if the patient recurs
• Patient followed up quarterly for 2 years and then semi-annually for 3 years
Comment by Oilminerdeluxe on Mar 22, 2024 3:59pm
Ungodly frustrating. But what can you do? Hope we get a nice update whenever it arrives.
Comment by Eoganacht on Mar 22, 2024 4:10pm
I think this is good. The trial still ends at 450 days past initial response, but Theralase will continue to compile durable response data. I don't think any prospective treatment we've heard about so far will be able to compete with Ruvidar PDT's durable response and Theralase will have the data to prove it.
Comment by Oilminerdeluxe on Mar 22, 2024 4:26pm
Hope you are right. We deserve a boost or two upwards. Hopefully, Roger's well of funds will not dry out going forward when the next need arises.. 
Comment by Eoganacht on Mar 22, 2024 4:36pm
I'm hoping that Theralase has already made a deal but that it's dependent on getting BTD. As of 4 days ago (March 18 Corporate Presentation) Theralase was still projecting BTD in the first half of 2024.
Comment by Oilminerdeluxe on Mar 22, 2024 4:54pm
Good. I didn't even know a new presentation was out, lol. That sounds within our grasp. Fingers crossed.  
Comment by DJDawg on Mar 22, 2024 5:47pm
any changes on the March 18 slide deck vs the previous one?
Comment by Alamir1111 on Mar 22, 2024 6:32pm
Oct 23 presentation shows Resarch capital as analyst March  18 no mention of them 
Comment by Alamir1111 on Mar 22, 2024 7:15pm
Premarket. Study device .projected mid 2023 end 2025 https://www.fda.gov/medical-devices/classify-your-medical-device/how-determine-if-your-product-medical-device#:~:text=Medical%20devices%20range%20from%20simple,kits%2C%20and%20blood%20glucose%20meters.
Comment by Mikee3003 on Mar 22, 2024 7:15pm
Eoganacht - I very much doubt a deal is in place dependent on getting BTD. If this was the case TLT would be handcufed with a LOI and I would certainly expect that a if there was a signed LOI it would be considered material information and a news release would need to be issued. 
Comment by Eoganacht on Mar 23, 2024 11:48am
Mikee3003 - as a secret agent for Theralase management, don't you think I'd know better than you? But maybe I'm just another poor schnook long who can't resist speculating about his Hail Mary pass retirement funding  longshot. Eh?
Comment by Oilminerdeluxe on Mar 23, 2024 12:20pm
Ha ha, good one!
Comment by DeathXray33 on Mar 23, 2024 12:35pm
"I'm just another poor schnook long who can't resist speculating about his Hail Mary pass retirement funding longshot." Lol... I'm right next to you. We'll be able to go camping, hiking & fishing a lot more. Roger & Sherri are awesome!!!
Comment by menoalittle on Mar 23, 2024 12:43pm
>> But maybe I'm just another poor schnook long who can't resist speculating about his Hail Mary pass retirement funding  longshot. Hey, I'm right there with you, eoganacht ! (for 5 years or so now... and it's getting mighty long in the tooth.) but, what do I know...    
Comment by Eoganacht on Mar 22, 2024 4:31pm
Once Ruvidar PDT is approved Theralase will be able to point to it's superior efficacy immediately and it's superior durable response will emerge more and more over time as Ruvidar maintains it's CR rate while Adstliladrin (for example) declines. With safety and only one or two treatments required Ruvidar will become the obvious choice.
Comment by Johnandrose22 on Mar 22, 2024 4:42pm
It is stunning to me that our primary source of understanding, guidance and perspective comes from Eoganacht and not the company. Thank God for this good and generous man to share his insights with us.  I can't imagine trying to sustain motivation and enthusiasm for our investment without him. How do people who are not on this board understand anything the company has done? Maybe ...more  
Comment by Mikee3003 on Mar 22, 2024 7:42pm
JohnandRose22 - Perhaps our friend Eoganacht is the "unofficial" communications person for Theralase??? Call me paranoid, suspicious.........are there any communications with Theralase's executive members or any employees?........hmmmmmmmmm   
Comment by Johnandrose22 on Mar 22, 2024 7:56pm
Ah, Mikee3003, thank you....After over 10 years investing in this company and attending  this forum there is little that can surprise me. My dilemma is this.....At this point, I trust the integrity, honesty, guidance of Eoganacht and others on this board more than I do the company's CEO and his administration. I don't think I'm alone with this. That's a problem.
Comment by judgesmails on Mar 22, 2024 8:37pm
Interesting perspective and I agree to some extent. I think the company is continually trying to succeed, but without a doubt they have dropped the ball at times.  Mostly a victim of 'the system' (& all the covid bullsh--), but some of the blame is on Theralase leadership also. Pre BDT is supposed to be in the rear view mirror.  But not a peep about that.  Should be at ...more  
Comment by Eoganacht on Mar 22, 2024 4:03pm
Theralase is now following up with patients for 60 months - exactly the same time period as Ferring is using with Adstiladrin treatments. This will facilitate a durable reponse comparison of the two treatments.
Comment by Donein25 on Mar 23, 2024 2:20pm
These lengthy additional surveillance times were never part of the original or even the optimized trial. It is important to remember that accelerated approval is now only granted with a plan in place for additional confirmatory surveillance in single arm trials. 60 months sure fits the bill for an additional surveillance plan under AA. I'm not saying that AA is just around the corner, but this ...more  
Comment by riverrrow on Mar 23, 2024 4:11pm
I'm sure everybody here would agree that AA would be huge.  The sooner the better.  Thanks for your post.
Comment by Longholder99 on Mar 23, 2024 6:07pm
Does it make sense that if AA is in the crosshairs.  Enrollment has stalled because after AA is acheived they can start charging money for treatments.  Saving the bank account   Would explain trial parameter changes as well.   Just a thought.  
Comment by StevenBirch on Mar 23, 2024 8:05pm
Would also explain why Roger is doing the small PPs every couple of months, I doubt they can keep going back to the same people if there was going to be a major delay. They must have some idea they are close and we just have to suffer these little price corrections until it all happens. 
Comment by riverrrow on Mar 23, 2024 10:21pm
While the number of patients that have reached 450 days is much smaller than the goal of 100 patients  and therefore the confidence level  in the CR% is smaller than desired, surely the lack of side effects and especially lack of serious side effects is a huge plus that should warrant huge consideration at this stage of the trial.  BTD an AA here we come.
Comment by Galaxym31 on Mar 24, 2024 12:22pm
Powers that be should stop torturing cancer victims with multiple treaments and severe side effects eh .
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250